A Agilent Technologies Inc.

Agilent Collaborates With SGS to Release New US EPA Method for the Analysis of Dioxins Using GC/TQ

(NYSE: A) announced today a collaboration with has resulted in a new GC/TQ method, the SGS AXYS Method 16130, approved by the US EPA as an alternative method for the future regulation and detection of dioxins.

Dioxins are a group of chemical compounds that are considered persistent environmental pollutants and subsequently find their way into the food chain. These chemicals are listed as persistent organic pollutants under the United Nations Stockholm Convention and are therefore regulated globally, meaning that accurate, reliable testing methods for dioxins are essential.

The previous US EPA dioxin testing method, EPA 1613B, required the use of magnetic sector instruments. These aging platforms are both difficult and expensive to use and maintain and therefore suffer from decreasing vendor and instrument availability.

“There was a crucial need for an alternative testing method as the current promulgated method of testing relies on 30-year-old mass spectrometry technology which is no longer being supported by most instrument manufacturers,” said Coreen Hamilton, a senior scientist with SGS Environmental, Health, and Safety who worked on the project. “We have worked in close collaboration over the past two years with the EPA and equipment manufacturers, including Agilent, to find a new method that would take advantage of the latest technological advancements such as modern tandem mass spectrometers.”

This new technology is already widely used in contract testing labs and is less expensive to purchase, operate, and maintain, increasing the number of laboratories able to perform this testing.

“This collaboration between Agilent, SGS AXYS, and the US EPA shows our commitment to provide the tools for labs to ensure a safer and healthier environment for all,” stated Tarun Anumol, Director, Global Environment & Food Markets, at Agilent. “The creation of this new method to analyze dioxins and furans using a GC/TQ allows environmental labs the ability to employ the newest technology to measure these contaminants more accurately and reliably while allowing them to reduce operational and laboratory costs at the same time.”

“This effort also shows Agilent’s continued commitment to support environmental testing as a market leader in this space for over 40 years,” Anumol added.

The newly approved Agilent SGS AXYS Method 16130 is set to become a key testing solution for environmental laboratories testing regulated contaminants. This new method will greatly reduce exposure to dioxins found in soil, agricultural land, and water.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. In its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
04/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch